140 related articles for article (PubMed ID: 37192745)
21. PRADclass: Hybrid Gleason Grade-Informed Computational Strategy Identifies Consensus Biomarker Features Predictive of Aggressive Prostate Adenocarcinoma.
Balraj AS; Muthamilselvan S; Raja R; Palaniappan A
Technol Cancer Res Treat; 2024; 23():15330338231222389. PubMed ID: 38226611
[TBL] [Abstract][Full Text] [Related]
22. LncRNA weighted gene co-expression network analysis reveals novel biomarkers related to prostate cancer metastasis.
Liu M; Chen MY; Huang JM; Liu Q; Wang L; Liu R; Yang N; Huang WH; Zhang W
BMC Med Genomics; 2022 Dec; 15(1):256. PubMed ID: 36514044
[TBL] [Abstract][Full Text] [Related]
23. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
24. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
25. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
26. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract][Full Text] [Related]
27. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.
Xu B; Tao T; Wang Y; Fang F; Huang Y; Chen S; Zhu W; Chen M
Tumour Biol; 2016 Oct; 37(10):14141-14151. PubMed ID: 27524492
[TBL] [Abstract][Full Text] [Related]
28. Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response.
Zhang X; Wang Y; Chang Y; Wang J; Yan S; Xiao Y; Guo T; Lou Y; Ma J; Xu W; Ren S
Arch Esp Urol; 2023 May; 76(3):215-231. PubMed ID: 37340527
[TBL] [Abstract][Full Text] [Related]
29. Identification of FAM107A as a potential biomarker and therapeutic target for prostate carcinoma.
Ma YF; Li GD; Sun X; Li XX; Gao Y; Gao C; Cao KX; Yang GW; Yu MW; Wang XM
Am J Transl Res; 2021; 13(9):10163-10177. PubMed ID: 34650688
[TBL] [Abstract][Full Text] [Related]
30. Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer.
He T; Zhang Y; Li X; Liu C; Zhu G; Yin X; Zhang Z; Zhao K; Wang Z; Zhao P; Wang K
World J Surg Oncol; 2022 Jun; 20(1):174. PubMed ID: 35650630
[TBL] [Abstract][Full Text] [Related]
31. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma.
Wu ZY; Wang SG; Li Q; Zhao QS; Shao MM
Math Biosci Eng; 2019 Dec; 17(3):2037-2047. PubMed ID: 32233522
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
[TBL] [Abstract][Full Text] [Related]
33. Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.
Li Y; Yang Z
Pathol Res Pract; 2018 Nov; 214(11):1811-1817. PubMed ID: 30195637
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
37. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
38. Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts.
Zhang C; Chen T; Li Z; Liu A; Xu Y; Gao Y; Xu D
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32856039
[TBL] [Abstract][Full Text] [Related]
39. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
[TBL] [Abstract][Full Text] [Related]
40. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.
Wang L; Zhang J; Yang X; Chang YW; Qi M; Zhou Z; Zhang J; Han B
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):301-7. PubMed ID: 23917306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
